首页> 外文期刊>Bone marrow transplantation >Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant.
【24h】

Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant.

机译:首次异体移植后血液恶性肿瘤复发后使用降低强度条件进行第二次异体移植的结果。

获取原文
获取原文并翻译 | 示例
           

摘要

Disease relapse following an allogeneic transplant remains a major cause of treatment failure, often with a poor outcome. Second allogeneic transplant procedures have been associated with high TRM, especially with myeloablative conditioning. We hypothesized that the use of reduced-intensity conditioning (RIC) would decrease the TRM. We performed a retrospective national multicentre analysis of 71 patients receiving a second allogeneic transplant using RIC after disease relapse following an initial allogeneic transplant. The majority of patients had leukaemia/myelodysplasia (MDS) (N=57), nine had lymphoproliferative disorders, two had myeloma and three had myeloproliferative diseases. A total of 25% of patients had unrelated donors. The median follow-up was 906 days from the second allograft. The predicted overall survival (OS) and TRM at 2 years were 28 and 27%, respectively. TRM was significantly lower in those who relapsed late (>11 months) following the first transplant (2 years: 17 vs 38% in early relapses; P=0.03). Two factors were significantly associated with a better survival: late relapse (P=0.014) and chronic GVHD following the second transplant (P=0.014). These data support our hypothesis that the second RIC allograft results in a lower TRM than using MA. A proportion of patients achieved a sustained remission even when relapsing after a previous MA transplant.
机译:同种异体移植后的疾病复发仍然是治疗失败的主要原因,通常结果不佳。第二个同种异体移植程序已与高TRM相关,尤其是与清髓条件有关。我们假设降低强度的调节(RIC)的使用会降低TRM。我们对首次异体移植后疾病复发后使用RIC接受第二次异体移植的71例患者进行了回顾性国家多中心分析。大多数患者患有白血病/骨髓增生异常(MDS)(N = 57),其中9位患有淋巴增生性疾病,2位患有骨髓瘤,3位患有骨髓增生性疾病。共有25%的患者有无关的供体。从第二次同种异体移植开始,中位随访时间为906天。 2年时的预测总体生存率(OS)和TRM分别为28%和27%。在首次移植后晚期(> 11个月)复发的患者中,TRM显着降低(2年:17%vs早期复发的38%; P = 0.03)。有两个因素与更好的生存率显着相关:第二次移植后的晚期复发(P = 0.014)和慢性GVHD(P = 0.014)。这些数据支持我们的假设,即同种异体移植第二次RIC导致的TRM低于使用MA的TRM。即使在先前的MA移植后复发,也有一部分患者实现了持续缓解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号